Silence Therapeutics plc
SLNCF
$0.95
$0.451490.53%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 41.55% | -41.87% | -36.66% | 16.85% | 40.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.55% | -41.87% | -36.66% | 16.85% | 40.89% |
| Cost of Revenue | -4.11% | -28.39% | -41.42% | -37.87% | -6.26% |
| Gross Profit | 72.94% | -53.10% | -32.42% | 88.12% | 115.33% |
| SG&A Expenses | 6.25% | 4.51% | -1.94% | -0.28% | 8.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.04% | -9.22% | -21.66% | -16.54% | 1.43% |
| Operating Income | 0.83% | -10.09% | 12.67% | 31.76% | 13.13% |
| Income Before Tax | 11.50% | -19.76% | 18.72% | 32.60% | 10.61% |
| Income Tax Expenses | -44.02% | 109.07% | 120.90% | 125.22% | 113.57% |
| Earnings from Continuing Operations | 12.20% | -43.47% | 0.01% | 16.57% | -7.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.20% | -43.47% | 0.01% | 16.57% | -7.00% |
| EBIT | 0.83% | -10.09% | 12.67% | 31.76% | 13.13% |
| EBITDA | 0.82% | -10.13% | 12.90% | 32.14% | 13.40% |
| EPS Basic | 30.10% | -16.47% | 14.55% | 26.21% | 7.48% |
| Normalized Basic EPS | 29.99% | 4.89% | 31.57% | 40.17% | 20.86% |
| EPS Diluted | 30.10% | -16.47% | 14.55% | 26.21% | 7.48% |
| Normalized Diluted EPS | 29.99% | 4.89% | 31.57% | 40.17% | 20.86% |
| Average Basic Shares Outstanding | 24.68% | 21.50% | 18.36% | 15.99% | 15.24% |
| Average Diluted Shares Outstanding | 24.68% | 21.50% | 18.36% | 15.99% | 15.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |